Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,721 to 1,740 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity. | PLoS One | 2021 | 33886614 | PubTator, text mining | PubMed |
| Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June-October 2020. | Emerg Infect Dis | 2021 | 33883059 | PubTator, text mining | PubMed |
| The role of nanotechnology in current COVID-19 outbreak. | Heliyon | 2021 | 33880422 | PubTator, text mining | PubMed |
| Epigenomics in COVID-19; the link between DNA methylation, histone modifications and SARS-CoV-2 infection. | Epigenomics | 2021 | 33876664 | PubTator, text mining | PubMed |
| PRRSV Promotes MARC-145 Cells Entry Into S Phase of the Cell Cycle to Facilitate Viral Replication via Degradation of p21 by nsp11. | Front Vet Sci | 2021 | 33869322 | PubTator, text mining | PubMed |
| Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. | Front Immunol | 2021 | 33859652 | PubTator, text mining | PubMed |
| SARS-CoV-2 one year on: evidence for ongoing viral adaptation. | J Gen Virol | 2021 | 33855951 | PubTator, text mining | PubMed |
| Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir. | ACS Pharmacol Transl Sci | 2021 | 33855277 | PubTator, text mining | PubMed |
| Comprehensive omic characterization of breast cancer in Mexican-Hispanic women. | Nat Commun | 2021 | 33854067 | PubTator, text mining | PubMed |
| The percentages of SARS-CoV-2 protein similarity and identity with SARS-CoV and BatCoV RaTG13 proteins can be used as indicators of virus origin. | J Proteins Proteom | 2021 | 33850392 | PubTator, text mining | PubMed |
| Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS- CoV-2 infection: An in silico Approach. | Virusdisease | 2021 | 33842675 | PubTator, text mining | PubMed |
| In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach. | In Silico Pharmacol | 2021 | 33842190 | PubTator, text mining | PubMed |
| Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. | Comput Struct Biotechnol J | 2021 | 33841751 | PubTator, text mining | PubMed |
| Structure and Expression of Large (+)RNA Genomes of Viruses of Higher Eukaryotes. | Biochemistry (Mosc) | 2021 | 33838627 | PubTator, text mining | PubMed |
| Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins' Mimicry of Human Protein Interactions. | Front Hum Neurosci | 2021 | 33833673 | PubTator, text mining | PubMed |
| Epigenetic Lens to Visualize the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection in COVID-19 Pandemic. | Front Genet | 2021 | 33828579 | PubTator, text mining | PubMed |
| Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. | Mol Psychiatry | 2021 | 33828235 | PubTator, text mining | PubMed |
| An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies. | Gene Rep | 2021 | 33821222 | PubTator, text mining | PubMed |
| Treading a HOSTile path: Mapping the dynamic landscape of host cell-rotavirus interactions to explore novel host-directed curative dimensions. | Virulence | 2021 | 33818275 | PubTator, text mining | PubMed |
| A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. | 3 Biotech | 2021 | 33816047 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=87